Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01591473 · ClinicalTrials.gov registry record · Phase 1
Safety Study of FluMist With and Without Ampligen
A Phase 1 study, sponsored by AIM ImmunoTech.
- Terminated
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT01591473 is a Phase 1 study that was terminated before completion, run by AIM ImmunoTech. The registered enrollment target is 55 participants.
The verdict
NCT01591473, a Phase 1 study, was terminated before completion, sponsored by AIM ImmunoTech.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate FluMist with and without Ampligen in healthy volunteers.
Interventions
- DRUG Placebo
- DRUG Poly I:Poly C12U 50 ug
- DRUG Poly I:Poly C12U 200 ug
- DRUG Poly I:Poly C12U 500 ug
- DRUG Poly I:Poly C12U 1250 ug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2012-04 |
| Est. Completion | 2015-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01591473
The ClinicalTrials.gov registry entry for NCT01591473 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AIM ImmunoTech, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01591473 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01591473 about?
NCT01591473 is a clinical study titled "Safety Study of FluMist With and Without Ampligen". The purpose of this study is to evaluate FluMist with and without Ampligen in healthy volunteers.
What is the current status of trial NCT01591473?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2012-04. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01591473?
The interventions under investigation include: Placebo (DRUG), Poly I:Poly C12U 50 ug (DRUG), Poly I:Poly C12U 200 ug (DRUG), Poly I:Poly C12U 500 ug (DRUG), Poly I:Poly C12U 1250 ug (DRUG).
Who is sponsoring clinical trial NCT01591473?
This trial is sponsored by AIM ImmunoTech, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.